Vaccination is Important to Your Kids


Published on

Hilleman Laboratories is a joint-venture between Merck & Co., a global research-driven pharmaceutical company and Wellcome Trust, a global charitable foundation dedicated to achieving extraordinary improvements in Child Health.

Published in: Health & Medicine, Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Vaccination is Important to Your Kids

  1. 1. Our commitment to Global Health
  2. 2. WELCOME TO HILLEMAN LABORATORIES Bridging scientific research and industry to develop effective, affordable and sustainable vaccines for developing world.
  3. 3. Developing Vaccines for Global Health
  4. 4. Tomorrow... is our concern and we care
  5. 5. Developing immunity.. Promising well being
  6. 6. Life is precious.. Vaccination to preserve it
  7. 7. Protecting life and ensuring healthy growth
  8. 8. Affordable and accessible vaccines for the developing nations
  9. 9. OUR IDENTITY Hillemanlabs @ Nanotechnology Building, Jamia Hamdard Striving towards a healthier world since September 2009 Joint Initiative to build a vaccine R&D facility with focus on developing world Devoted team of 30 scientists with expertise in Vaccine Development and Testing Operating with core divisions of Upstream, Downstream, Formulations and Analytical Labs Mission to develop thermo stable, efficacious and affordable vaccines
  10. 10. DR. MAURICE HILLEMAN A Pioneer in Vaccine Development "Discoveries of the cause for diseases and their prevention by vaccines... have been a hallmark for twentieth century medicine and provide a remarkable heritage for the people of the future." Maurice R.Hilleman, PhD, DSc Senior Vice President, 1957-1984 Merck Sharp & Dohme Research Laboratories
  11. 11. OUR APPROACH HL carries out R&D and Clinical Assessment activities to develop vaccines for diseases that constitute almost 90% of the global burden of diseases HL carries out R&D and Clinical Assessment activities to develop vaccines for diseases that constitute almost 90% of the global burden of diseases HL is forging partnerships with Government, Policy Makers, Public & Private Enterprises, Research Institutes and NGOs to strengthen public health systems and immunization programs HL is forging partnerships with Government, Policy Makers, Public & Private Enterprises, Research Institutes and NGOs to strengthen public health systems and immunization programs
  12. 12. OUR APPROACH
  13. 13. Apply Focus Partner OUR VISION Philanthropy Science Business
  14. 14. OUR DREAM Vaccine for every child Immunize and protectHealthier force of tomorrow
  15. 15. Facility (GLP class) Scientists Infrastructure Novel Immunization Platform (HL) OUR COMMITMENT Reduced footprint and affordability Thermostability Ease of administration
  16. 16. OUR ADVISORS (Director, Emory Vaccine Center) Dr. Rafi Ahmed Executive Director, Icddr,b Dhaka, Bangladesh Dr. John Clemens (Prof. & Chairman Dept. of Pediatrics & Child Health, Aga Khan UMC, Pakistan) Dr. Zulfiqar Bhutta (Assistant Director- General, Health Systems and Innovation) Dr. Marie-Paule Kieny (Board Member and Advisor for Foundations in Switzerland, Uganda, Thailand and US) Timothy Nielander (CEO, The Global Partnership for Education) Alice Albright (President & Chief Executive Officer, Vedantra) Dr. Allan Shaw (Chairman, African Leaders Malaria Alliance and Chairman, Board AIDS Fund) Ms. Joy Phumaphi (President, Health Foundation of India) Dr. K. Srinath Reddy Ms. Helen Rees Professor of Medicine, Global Health, and Pediatrics Associate Director, Emory Vaccine Center Director, Emory Vaccine Policy and Development Walter A. Orenstein, MD Professor Helen Rees OBE MB BChir, MA (CANTAB), MRCGP, DCH, DRCOG Mr. Michel Greco Former President of Aventis Pasteur
  17. 17. OUR BOARD MEMBERS Director, Hilleman Laboratories (Senior Vice President and Head, Global Vaccine Franchise, Merck) Dr. James R. Baker Director, Hilleman Laboratories (President – Vaccine Division, Merck) Dr. Julie Gerberding Director, Hilleman Laboratories (Director – Technology Transfer, Wellcome Trust) Dr. A.E. Bianco Director, Hilleman Laboratories (Senior Vice President, Manufacturing Division, Merck) Sanat Chattopadhyay Director, Hilleman Laboratories (Chief Operating Officer, Wellcome Trust) Simon Jeffreys (Chairman, Hilleman Laboratories) Dr. Gerd Zeittlmeissl Director – Hilleman Laboratories (Head of Microbial Pathogenesis (Sanger Center)) Prof. Gordon Dougan
  18. 18. OUR MANAGEMENT Chief Executive Officer (MSD Wellcome Trust, Hillemanlabs) Dr. Davinder Gill Vice President - Finance & Company Secretary, (MSD Wellcome Trust, Hillemanlabs) Mr. Naveen K Amar Vice President - HR, Admin & IT, (MSD Wellcome Trust Hillemanlabs) Mr. Jaideep Mukherjee Vice President - Business Development (MSD Wellcome Trust, Hillemanlabs) Mr. Atin Tomar Vice President – R&D Dr. Zimra Israel 
  19. 19. VACCINE RESEARCH OVERVIEW 01 02 03 04 05 06 07 08 Antigen Identification Candidate screening Responsiveness Host Protection Immunogenicity Toxicity Selection Immune response Responsiveness in large cohort Antigen Production (Laboratory-scale) Screening of growth medium Screening of growth parameters Manufacturing (Industrialscale) Process Scale-up Process optimization Clinical Trail (Phase I) Safety Non-endemic Healthy Adults> 20 About 3 months Adverse effects Clinical Trial (Phase II) Immunogenicity Endemic infected/noninf.>100 About 3 years Immune responses Clinical Trail (Phase III) Efficacy Endemic infected/healthy>1000 Up to 5 years Protection
  20. 20. VACCINE RESEARCH OVERVIEW Hilleman Laboratories works extensively to bridge the gap between current vaccine candidate reliance on cold chain and low accessibility & build a new platform technology for development of thermo-stable and affordable vaccines
  21. 21. The current project undertaken at Hilleman Laboratories is to heat stabilize the existing vaccine candidate Development of a thermo-stable oral thin film or granule- based rotavirus vaccine to allow for greater stability and reduce cold chain burden Hilleman laboratories is open to collaboration for development of innovative vaccine delivery methods to develop the initial assay for the project Hilleman Labs first project to focus on affordable access to life-saving Rotavirus vaccine to resource limited nations R&D AT HILLEMAN LABORATORIES
  22. 22. Microbial and Mammalian culture Filtration and chromatographic separation Formulation development and lyophilization/spray-dryiing R&D AT HILLEMAN LABORATORIES Screening and Identifying potential candidates with focus on heat stabilization Seeding virus – cell culture – potency assay – Formulation Development Pre-clinical evaluation – viability for commercial scale-up – Development of Delivery technology Up-Stream Process Downstream Process Formulation & Analytics
  23. 23. Marketing and Distribution Phase 3 Large Scale Manufacturing Late Development Phase IIIClinical Trial -> Registration R&D AT HILLEMAN LABORATORIES Phase 2 Early Development Lead –> Phase I /II Clinical Trial Phase 1 Basic Research Target -> Lead Candidate
  24. 24. R&D AT HILLEMAN LABORATORIES Global Vaccine Needs Feasibility Hilleman Strengths Trans-HL management and advisory group consultation for program synergy HL Lead Project HL Scientific Advisory Leadership Projects adopted HL Leadership Program Plan Review Review Strengths, Weakness Research Proposal (from extramural, intramural, biotech, foundation)
  25. 25. R&D AT HILLEMAN LABORATORIES Up-Stream Process Downstream Process Analytical
  26. 26. OUR CULTURE
  27. 27. Latest happenings Best Industrial Partnership in India
  29. 29. HILLEMAN LABORATORIES PVT. LTD. Hilleman Laboratories Pvt. Ltd. 2nd Floor, Nanotechnology Building, Jamia Hamdard, Hamdard Nagar, New Delhi – 110062 India. Ph: +91 (11) 3099 7700 Fax: +91 - (11) 3099 7711 Email: Website: Office Contact: